Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 

Analyst Coverage

Firm Analyst
Canaccord Genuity
John Newman Ph.D.
Cowen
Eric Schmidt Ph.D.
Credit Suisse
Alethia Young
Goldman Sachs
Terence Flynn Ph.D.
JP Morgan
Anupam Rama
Leerink Swann & Company
Michael Schmidt Ph.D.
Needham & Company
Chad Messer Ph.D.
Oppenheimer & Co.
Leah Rush Cann
RBC Capital Markets
Kennen MacKay Ph.D.
SunTrust Robinson Humphrey
Yatin Suneja

Agios Pharmaceuticals, Inc. – IR Site is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Agios Pharmaceuticals, Inc. – IR Site's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Agios Pharmaceuticals, Inc. – IR Site or its management. Agios Pharmaceuticals, Inc. – IR Site does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.